bioMérieux S.A.
BMXMF
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.16B
Close$
$59.72
34.6% downside
Current Fair Value
34.6% downsideOvervalued by 34.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.16 Billion |
|---|---|
| Enterprise Value | $10.92 Billion |
| Dividend Yield | $1.13 (1.18%) |
| Earnings per Share | $3.37 |
| Beta | 0.57 |
| Outstanding Shares | 117,760,000 |
Return
| Return on Equity | 19.51% |
|---|---|
| Return on Assets | 14.73% |
| Return on Invested Capital | 24.93% |
Valuation & Multiples
| P/E Ratio | 21.17 |
|---|---|
| PEG | 52.36 |
| Price to Sales | 1.34 |
| Price to Book Ratio | 2.54 |
| Enterprise Value to Revenue | 1.35 |
| Enterprise Value to EBIT | 9.6 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 28, 2026
EPS Estimate
$2.32
Average shareholder expectationRevenue Estimate
$2.21 B
Average shareholder expectationNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
$2.83
Average shareholder expectationRevenue Estimate
$2.43 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About bioMérieux S.A.
14,894 employees
CEO: Pierre Boulud bioMérieux S.A. is a global entity operating across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, specializing in the development and production of in vitro diagnostic solutions. The company's sophisticated systems...